ScinoPharm (Changshu) Pharmaceuticals and Sundia MediTech Company Ltd. has announced a strategic alliance to seek more opportunities for collaboration in Contract Research and Manufacturing Services (CRAMS) in mainland China and to tap into this large and growing business potential.
The cooperation will combine Sundia's diversified technical know-how and capabilities in new drug R&D with ScinoPharm's process R&D and commercial production advantages, especially in the field of highly potent oncological APIs.
"Resources from our Changshu site in Jiangsu province, China, and the Shanghai-based CRO company Sundia will be combined to establish a robust collaboration with single-source solutions to address the increasing number of multinational companies shifting their drug development research and clinical trials in China," reported Dr. Jo Shen, CEO of ScinoPharm Taiwan and chairman of ScinoPharm Changshu.
"Sundia has established long-standing and strong relationships with a number of big pharmaceuticals and small/ medium-sized biotech companies from the US, Europe, Japan and South Korea in the fields of chemistry, biology, preclinical, formulation and API manufacture, helping our clients and partners to bring drugs to the market efficiently," said Dr. Chen Chen, Sundia's CEO." Sundia is very pleased to have the opportunity to work with ScinoPharm, a world-leading process R&D and API manufacturing service provider. I am sure that the strategic partnership between Sundia and ScinoPharm will have mutual benefits, helping each other to thrive in both international and China Market."
Founded by a group of veterans from the US biopharmaceutical industry in 2004, Sundia MediTech Company Ltd. is a Shanghai-based Clinical Research Organization (CRO) providing drug discovery and development services worldwide with a research team of over 600 employees. Currently, Sundia has successfully established collaborations with over 100 clients in North America, Europe, and Japan, according to the company.
Founded in 2009, ScinoPharm Changshu is located at Changshu Economic Development Zone in Jiangsu Province. ScinoPharm Changshu is a subsidiary of ScinoPharm Taiwan Ltd., which is a process R&D and API manufacturing service provider to the global pharmaceutical industry. With research and manufacturing facilities in both Taiwan and China, ScinoPharm offers services ranging from custom synthesis for early phase pharmaceutical activities to brand companies as well as APIs for the generic industry. The company also provides a vertically integrated, one-stop-shopping service for its API customers by expanding into the field of oncological injectable formulations.
Click here for the complete issue.